Johnson & Johnson (JNJ) continues to be a solid player in the
biotech sector as its positions were boosted by multiple management firms including
Norris Perne & French LLP MI,
Griffin Asset Management Inc and
Toth Financial Advisory Corp. Despite some setback in litigation related to talc bankruptcy, the company managed a significant
$700 million settlement with US states. With continuous innovation, J&J also made it to Fortune's 2024 Most Innovative Companies list, suggesting strong fundamentals. The company also reported positive results from the
nipocalimab Phase 3 Vivacity-MG3 study, which can contribute to future growth. Additionally, J&J is actively
diversifying its assets with the acquisition of
Proteologix and
Shockwave Medical in multi-billion-dollar deals. However, not all updates about the company are positive.
Sell-off of JNJ shares by various firms, including Fidelity D&D Bancorp Inc and New England Research & Management Inc, suggest some market uncertainty. Furthermore, its reputable talc bankruptcies faced criticism, even deemed as 'fraudulent' by some victims.
Johnson Johnson JNJ News Analytics from Thu, 14 Sep 2023 07:00:00 GMT to Sun, 30 Jun 2024 18:11:39 GMT -
Rating 5
- Innovation 4
- Information 5
- Rumor -2
